This complimentary program is geared toward U.S. companies expanding or starting business in China as well as U.S. private equity funds looking to expand their investment portfolios by acquiring equity interests in Chinese companies.
During this interactive session, panelists will discuss the common pitfalls of and practical strategies for doing business in China, including:
- Current trends impacting U.S. companies investing and doing business in China
- Special issues involved in acquiring equity interests in Chinese companies
- China’s foreign exchange control regulations and what they mean to U.S. companies in China
- Considerations on capital structure and available financing options for investments in China
- Managing employer-employee relationships in China
- Challenges of and opportunities arising from the current economic situations in the United States and China
Featured Speakers:
- H. Timothy Lopez, A.O. Smith, Associate General Counsel
- Kok-Chi Tsim, JPMorgan Chase, Managing Director and Senior Relationship Executive
- Z. Julie Lee, Foley International Business Transactions Partner
- Barry L. Grossman (Moderator), Foley Intellectual Property Of Counsel
Co-Sponsor:
People
Related Insights
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Article
FTC Finalizes Rule Against Employee Noncompetes
On April 23, 2024, the Federal Trade Commission voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Health Care Law Today
FDA Continues to Take Stance That it Will Not Issue CBD Rules
The FDA recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of CBD and a new regulatory pathway is needed.